What is the 13F Pro Quality Score for SANA?

13F Pro ranks Sana Biotechnology, Inc. (SANA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SANA's current score at https://13fpro.ai/research/SANA (free sign-up required for the full ranking).

Which hedge funds own the most SANA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SANA include FMR, Flagship Pioneering, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SANA as soon as new 13F filings post.

Where does 13F Pro source SANA data?

All Sana Biotechnology, Inc. fundamentals and ownership data come directly from SEC EDGAR. Sana Biotechnology, Inc. files with the SEC under CIK 1770121. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SANA in?

Sana Biotechnology, Inc. (SANA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SANA research updated on 13F Pro?

SANA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Sana Biotechnology, Inc.(SANA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1770121 SANA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SANA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Sana Biotechnology, Inc. (SANA), a Healthcare sector company. SANA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Sana Biotechnology, Inc. reports net income of $-47.2M, free cash flow of $-37.7M. Top institutional holders of SANA by reported 13-F value include FMR, Flagship Pioneering, BlackRock,, based on the most recent SEC filings. SANA trades on the Nasdaq exchange and files with the SEC under CIK 1770121. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SANA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sana Biotechnology, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-47.2M

Free Cash Flow

Q1 2026

$-37.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+31.4% YoY

$-244.2MFY 2025

FY18 —FY21 $-355.9MFY25 $-244.2M

Operating Income

+29.9% YoY

$-250.3MFY 2025

FY18 —FY21 $-356.9MFY25 $-250.3M

EPS (Diluted)

+55.1% YoY

$-0.96FY 2025

FY18 —FY21 $-2.14FY25 $-0.96

Total Assets

-63.1% YoY

$416.9MFY 2025

FY18 —FY21 $1.13BFY25 $416.9M

Op. Cash Flow

+42.7% YoY

$-143.8MFY 2025

FY18 —FY21 $-251.1MFY25 $-143.8M

Metric	FY 2025	FY 2021	FY 2018
Net Income	$-244.2M +31.4%	$-355.9M	—
Operating Income	$-250.3M +29.9%	$-356.9M	—
EPS (Diluted)	$-0.96 +55.1%	$-2.14	—
Total Assets	$416.9M -63.1%	$1.13B	—
Operating Cash Flow	$-143.8M +42.7%	$-251.1M	—

AI Insight: SANA Financial Trends

Cash burn has stabilized around $30–50M quarterly, but equity has eroded 65% since mid-2024 as the company funds R&D with no revenue.

• Operating cash outflow narrowed from $59M (Q2 2024) to $37M (Q1 2026), suggesting cost discipline or reduced spending intensity.

• Net losses remain volatile ($42–94M range) but Q3 2025 marked a low of $42M; Q1 2026 at $47M shows continued elevated burn.

• Shareholder equity compressed 65% from $340M (Q2 2024) to $119M (Q1 2026) amid persistent net losses and no revenue generation.

⚠ Equity runway at $119M with $37M quarterly burn implies ~3 quarters of capital remaining unless funding is secured.

⚠ No revenue reported across 8 quarters indicates pipeline remains pre-commercial; clinical or regulatory milestones critical.

AI Insight: SANA Ratio Trends

Sana Biotechnology remains deeply unprofitable with ROE deteriorating to -158.4% in Q1 2026, indicating accelerating cash burn and negative returns on shareholder capital.

• ROE collapsed from -94.5% in Q1 2025 to -158.4% in Q1 2026, worsening 64pp year-over-year.

• ROA declined from -44.4% in Q1 2025 to -50.5% in Q1 2026, indicating deteriorating asset efficiency.

⚠ Q4 2025 ROE spiked to -146.2%, suggesting a severe loss quarter; Q1 2026 worsened further to -158.4%.

⚠ Operating margin, NPM, and ROIC data entirely absent—opaque financial position limits visibility into path to profitability.

Get alerted when SANA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Sana Biotechnology, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SANA

FMR LLC
$107.8M37,430,284 sh
Flagship Pioneering Inc.
$72.0M25,001,856 sh
BlackRock, Inc.
$41.0M14,240,175 sh
STATE STREET CORP
$30.3M10,538,086 sh
CANADA PENSION PLAN INVESTMENT BOARD
$29.4M10,221,900 sh
VANGUARD CAPITAL MANAGEMENT LLC
$21.4M7,434,724 sh
BAILLIE GIFFORD & CO
$19.0M6,609,065 sh
GEODE CAPITAL MANAGEMENT, LLC
$12.0M4,181,973 sh
Marex Group plc
$11.5M3,999,100 sh
Integral Health Asset Management, LLC
$9.2M3,200,000 sh

Fund	Value	Shares
FMR LLC	$107.8M	37,430,284
Flagship Pioneering Inc.	$72.0M	25,001,856
BlackRock, Inc.	$41.0M	14,240,175
STATE STREET CORP	$30.3M	10,538,086
CANADA PENSION PLAN INVESTMENT BOARD	$29.4M	10,221,900
VANGUARD CAPITAL MANAGEMENT LLC	$21.4M	7,434,724
BAILLIE GIFFORD & CO	$19.0M	6,609,065
GEODE CAPITAL MANAGEMENT, LLC	$12.0M	4,181,973
Marex Group plc	$11.5M	3,999,100
Integral Health Asset Management, LLC	$9.2M	3,200,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SANA on your watchlist

Track score changes the day Sana Biotechnology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SANA a good stock to buy?

13F Pro's AI-powered analysis of Sana Biotechnology, Inc. (SANA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SANA are available on the SANA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SANA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SANA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sana Biotechnology, Inc.'s investment landscape.